Australia’s
ALS plans to raise the capital through a fully underwritten A$350 million institutional placement, according to an exchange statement Tuesday. The new shares will be offered at A$16.70 apiece, representing a 5.3% discount to Monday’s close. It will also undertake a non-underwritten share purchase plan of up to A$40 million.
Most of the proceeds will be used to fund organic investment in the company’s laboratory network, the filing said. The rest will be used on other ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
